Gain Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS


· June 30, · December 31,
· · · 2025 · · 2024
Assets · ·
Current assets: · ·
Cash and cash equivalents	$6,694,136	$10,385,863
Tax credits	317,844	271,079
Prepaid expenses and other current assets	2,294,723	945,536
Total current assets	9,306,703	11,602,478

Noncurrent assets:
Property and equipment, net	96,190	103,619
Internal-use software, net	127,857	134,268
Operating lease right-of-use assets	233,200	219,715
Restricted cash	36,278	31,695
Long-term deposits and other noncurrent assets	33,752	32,109
Total noncurrent assets	527,277	521,406
Total assets	$9,833,980	$12,123,884

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$2,713,013	$946,259
Operating lease liability - current	136,320	160,913
Other current liabilities	2,198,918	2,441,761
Deferred grant income - current	22,685	252,211
Loans - current	126,108	110,177
Total current liabilities	5,197,044	3,911,321

Noncurrent liabilities:
Defined benefit pension plan	522,676	443,623
Operating lease liability - noncurrent	92,851	53,598
Deferred grant income - noncurrent	—	47,441
Loans - noncurrent	325,359	328,327
Total noncurrent liabilities	940,886	872,989
Total liabilities	$6,137,930	$4,784,310

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of June 30, 2025 and December 31, 2024	$—	$—
Common stock, $0.0001 par value: 100,000,000 shares authorized; 30,771,321 and 27,132,588 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	3,078	2,713
Additional paid-in capital	94,642,942	88,779,318
Accumulated other comprehensive loss	584,083	(247,549)
Accumulated deficit	(81,194,908)	(60,783,717)
Loss of the period	(10,339,145)	(20,411,191)
Total stockholders’ equity	3,696,050	7,339,574
Total liabilities and stockholders’ equity	$9,833,980	$12,123,884

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.